EscharEx - MediWound

Drug Profile

EscharEx - MediWound

Alternative Names: EscharEx; EX-02

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MediWound
  • Class Enzymes; Skin disorder therapies
  • Mechanism of Action Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Leg ulcer; Wounds

Most Recent Events

  • 17 Jul 2018 MediWound plans a phase II trial for Leg ulcer (NCT03588130)
  • 16 Nov 2017 MediWound completes enrolment in a phase II trial for Leg ulcer and Wounds in Hungry and Israel
  • 01 Sep 2017 Topline safety data from a phase II trial in Wounds and Leg ulcer released by MediWound
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top